CARDISPAN 1G/5ML SOLUCIÓN INYECTABLE I.V., I.M. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

cardispan 1g/5ml solución inyectable i.v., i.m.

laboratorios grossman, s.a. - levocarnitina - levocarnitina....1g/5ml

CARNISIN 1 G / 10 ML SOLUCION ORAL Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

carnisin 1 g / 10 ml solucion oral

laboratorios leti, s.a.v - levocarnitina - levocarnitina....1,0 g

CARDISPAN 1G TABLETAS MASTICABLES. Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

cardispan 1g tabletas masticables.

laboratorios grossman, s.a. - levocarnitina - levocarnitina....1.000 g

CARNISIN 1G/10 ML SOLUCIÓN ORAL Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

carnisin 1g/10 ml solución oral

mercantil farmacÉutica, s.a (mefasa) - levocarnitina - levocarnitina....1,0 g

EFE-CARN 1G/5ML SOLUCIÓN INYECTABLE Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

efe-carn 1g/5ml solución inyectable

laboratorios pisa s.a. de c.v - levocarnitina - levocarnitina....1g

LEVOCARNITINE solution United States - English - NLM (National Library of Medicine)

levocarnitine solution

akorn - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 1 g in 10 ml - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology ). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

LEVOCARNITINE tablet United States - English - NLM (National Library of Medicine)

levocarnitine tablet

akorn - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 330 mg - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known.

LEVOCARNITINE- levocarnitine oral solution solution LEVOCARNITINE (levocarnitine oral solution- suguar free 1 g/10 ml solution United States - English - NLM (National Library of Medicine)

levocarnitine- levocarnitine oral solution solution levocarnitine (levocarnitine oral solution- suguar free 1 g/10 ml solution

novitium pharma llc - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine is indicated in the treatment of primary systemic carnitine deficiency. in the reported cases, the clinical presentation consisted of recurrent episodes of reye-like encephalopathy, hypoketotic hypoglycemia, and/or cardiomyopathy. associated symptoms included hypotonia, muscle weakness and failure to thrive. a diagnosis of primary carnitine deficiency requires that serum, red cell and/or tissue carnitine levels be low and that the patient does not have a primary defect in fatty acid or organic acid oxidation (see clinical pharmacology). in some patients, particularly those presenting with cardiomyopathy, carnitine supplementation rapidly alleviated signs and symptoms. treatment should include, in addition to carnitine, supportive and other therapy as indicated by the condition of the patient. levocarnitine is also indicated for acute and chronic treatment of patients with an inborn error of metabolism which results in a secondary carnitine deficiency. none known

LEVOCARNITINE injection, solution United States - English - NLM (National Library of Medicine)

levocarnitine injection, solution

american regent, inc. - levocarnitine (unii: 0g389fzz9m) (levocarnitine - unii:0g389fzz9m) - levocarnitine 200 mg in 1 ml - for the acute and chronic treatment of patients with an inborn error of metabolism which results in secondary carnitine deficiency. for the prevention and treatment of carnitine deficiency in patients with end stage renal disease who are undergoing dialysis. none known.

Levocarnitine Paediatric 30%w/v Oral Solution Malta - English - Medicines Authority

levocarnitine paediatric 30%w/v oral solution

cenote pharma ltd elizabeth house 13-19 london road newbury, berkshire rg14 1jl, united kingdom - levocarnitine - oral solution - levocarnitine 30 % (w/v) - other alimentary tract and metabolism products